Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights.
Consolidated quarterly financials:
Cash, cash equivalents and short-term investments of a total $249.9 million as of March 31, 2023, compared to $273.1 million in Dec. 31, 2022.
Net loss of $33.1 million, compared to $36.9 million for the same period in 2022.
R&D expenses of $19.3 million, compared to $15.5 million for the same prior year period.
G&A expenses of $14.0 million compared to $18.0 million for the same prior year period.
The company expects its current cash position and committed term …